%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Elena Ortiz-Zapater, Richard W. Lee, William Owen, Gregory Weitsman, Gilbert Fruhwirth, Robert G. Dunn, Michael J. Neat, Frank McCaughan, Peter Parker, Tony Ng, George Santis
MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 14 0 R/Contents 15 0 R/TrimBox[0 0 612 792]>>
endobj
14 0 obj
[16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R]
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref001)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref002)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref003)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref004)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref005)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref006)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref007)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref008)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref009)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref004)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref005)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref006)>>
endobj
28 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref007)>>
endobj
29 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref010)>>
endobj
30 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref011)>>
endobj
31 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref012)>>
endobj
32 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref013)>>
endobj
33 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref014)>>
endobj
34 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref013)>>
endobj
35 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref015)>>
endobj
36 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref014)>>
endobj
37 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref016)>>
endobj
38 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref016)>>
endobj
39 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref017)>>
endobj
40 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref018)>>
endobj
41 0 obj
<>/Border[0 0 0]/Dest(Rpone.0170798.ref010)>>
endobj
15 0 obj
[42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R 62 0 R 63 0 R]
endobj
42 0 obj
<>stream
q
0.83 0.64 0.02 0 k
409.4362 649.0205 m
414.1984 649.0205 l
h
f*
475.2567 622.9984 m
480.0189 622.9984 l
h
f*
498.0472 610.0157 m
502.8094 610.0157 l
h
f*
225.5811 558.0283 m
230.3433 558.0283 l
h
f*
234.7654 558.0283 m
239.5276 558.0283 l
h
f*
244.0063 558.0283 m
248.7685 558.0283 l
h
f*
253.1906 558.0283 m
257.9528 558.0283 l
h
f*
232.5543 544.989 m
237.3165 544.989 l
h
f*
302.5701 532.0063 m
307.2756 532.0063 l
h
f*
455.0173 519.0236 m
459.7795 519.0236 l
h
f*
464.2016 519.0236 m
468.9638 519.0236 l
h
f*
473.4425 519.0236 m
478.2047 519.0236 l
h
f*
482.6268 519.0236 m
487.389 519.0236 l
h
f*
342.085 505.9843 m
351.6094 505.9843 l
h
f*
336.9827 493.0016 m
346.5071 493.0016 l
h
f*
350.9291 493.0016 m
360.4535 493.0016 l
h
f*
364.9323 493.0016 m
374.4 493.0016 l
h
f*
378.8787 493.0016 m
388.4031 493.0016 l
h
f*
249.8457 480.0189 m
259.3701 480.0189 l
h
f*
439.8803 453.9969 m
449.4047 453.9969 l
h
f*
239.9811 402.0094 m
249.5055 402.0094 l
h
f*
226.3181 363.0047 m
235.8425 363.0047 l
h
f*
243.9496 350.022 m
253.474 350.022 l
h
f*
257.8961 350.022 m
267.4205 350.022 l
h
f*
271.8425 350.022 m
281.3669 350.022 l
h
f*
485.2913 336.9827 m
494.8157 336.9827 l
h
f*
0 g
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 706.0535 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 689.1023 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Epidermal)Tj
4.3936 0 Td
(growth)Tj
3.0728 0 Td
(factor)Tj
2.5455 0 Td
(receptor)Tj
3.5546 0 Td
(\(EGFR\))Tj
3.3335 0 Td
(tyrosine)Tj
3.4526 0 Td
(kinase)Tj
2.7496 0 Td
(inhibitors)Tj
4.1442 0 Td
(\(EGFR-TKIs\))Tj
5.6692 0 Td
(have)Tj
2.058 0 Td
(revo-)Tj
-34.9736 -1.3039 Td
(lutionised)Tj
4.1952 0 Td
(treatment)Tj
4.1329 0 Td
(of)Tj
1.0148 0 Td
(non-small)Tj
4.2803 0 Td
(cell)Tj
1.559 0 Td
(lung)Tj
2.0126 0 Td
(cancer)Tj
2.8403 0 Td
(\(NSCLC\))Tj
3.9798 0 Td
(in)Tj
1.0318 0 Td
(patients)Tj
3.3732 0 Td
(with)Tj
/F12 1 Tf
1.9956 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(mutations.)Tj
-32.9667 -1.2982 Td
(These)Tj
2.5681 0 Td
(mutations)Tj
4.2803 0 Td
(cause)Tj
2.3868 0 Td
(constitutive)Tj
4.8982 0 Td
(kinase)Tj
2.7496 0 Td
(activity)Tj
3.1181 0 Td
(and)Tj
1.7291 0 Td
(are)Tj
1.4513 0 Td
(oncogenic)Tj
4.3313 0 Td
(drivers)Tj
2.9991 0 Td
(in)Tj
1.0318 0 Td
(1020%)Tj
3.4015 0 Td
(of)Tj
-34.9452 -1.2983 Td
(Caucasian)Tj
4.3143 0 Td
(patients)Tj
3.3675 0 Td
(and)Tj
1.7291 0 Td
(up)Tj
1.2643 0 Td
(to)Tj
1.0261 0 Td
(50%)Tj
1.9275 0 Td
(of)Tj
1.0148 0 Td
(eastern)Tj
3.0784 0 Td
(Asians.[)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(])Tj
4.2577 0 Td
(Such)Tj
2.1769 0 Td
(mutations)Tj
4.2803 0 Td
(induce)Tj
2.9367 0 Td
(conformational)Tj
-31.3736 -1.3039 Td
(changes)Tj
3.4015 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(receptor)Tj
3.5546 0 Td
(that)Tj
1.7802 0 Td
(alter)Tj
1.9956 0 Td
(the)Tj
1.4683 0 Td
(dimerization)Tj
5.3631 0 Td
(interface,)Tj
3.9231 0 Td
(destabilize)Tj
4.388 0 Td
(the)Tj
1.4684 0 Td
(inactive)Tj
3.3392 0 Td
(state)Tj
2.0352 0 Td
(and)Tj
-35.223 -1.2983 Td
(increase)Tj
3.4695 0 Td
(kinase)Tj
2.7496 0 Td
(activity)Tj
3.1181 0 Td
(to)Tj
1.0261 0 Td
(50)Tj
1.1736 0 Td
(times)Tj
2.3867 0 Td
(that)Tj
1.7802 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(wild)Tj
1.9446 0 Td
(type)Tj
1.9162 0 Td
(\(WT\))Tj
2.4774 0 Td
(EGFR.[)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(])Tj
4.0366 0 Td
(The)Tj
/F12 1 Tf
1.7801 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(exon)Tj
2.1656 0 Td
(21)Tj
-35.0586 -1.2982 Td
(L858R)Tj
2.8062 0 Td
(and)Tj
1.7292 0 Td
(in-frame)Tj
3.719 0 Td
(exon)Tj
2.1656 0 Td
(19)Tj
1.1679 0 Td
(deletions)Tj
3.8211 0 Td
(account)Tj
3.3789 0 Td
(for)Tj
1.3889 0 Td
(85%)Tj
1.9276 0 Td
(of)Tj
1.0091 0 Td
(such)Tj
2.0636 0 Td
(mutations.[)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(])Tj
5.6579 0 Td
(Whilst)Tj
2.8857 0 Td
(responses)Tj
-33.7207 -1.304 Td
(are)Tj
1.4456 0 Td
(often)Tj
2.2847 0 Td
(impressive,)Tj
4.7112 0 Td
(resistance)Tj
4.1329 0 Td
(is)Tj
0.8503 0 Td
(inevitable.)Tj
4.3144 0 Td
(The)Tj
1.7801 0 Td
(commonest)Tj
4.9322 0 Td
(mechanism)Tj
4.8416 0 Td
(for)Tj
1.389 0 Td
(resistance)Tj
4.1328 0 Td
(is)Tj
-34.8148 -1.2982 Td
(acquisition)Tj
4.6261 0 Td
(or)Tj
1.0998 0 Td
(clonal)Tj
2.6249 0 Td
(expansion)Tj
4.2916 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
/F12 1 Tf
1.4683 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(exon)Tj
2.1656 0 Td
(20)Tj
1.1679 0 Td
(T790M)Tj
3.1521 0 Td
(mutation.)Tj
-22.9661 -1.2983 Td
(Amplification)Tj
5.7883 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(MET)Tj
2.2904 0 Td
(receptor)Tj
3.5546 0 Td
(represents)Tj
4.32 0 Td
(an)Tj
1.2018 0 Td
(important)Tj
4.286 0 Td
(alternative)Tj
4.4163 0 Td
(resistance)Tj
4.1329 0 Td
(mecha-)Tj
-33.6753 -1.2983 Td
(nism)Tj
2.2166 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2586 0 Td
(5)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
0.9241 0 Td
(6)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
0.9184 0 Td
(7)Tj
0 g
(].)Tj
1.2643 0 Td
(MET)Tj
2.2903 0 Td
(is)Tj
0.8504 0 Td
(a)Tj
0.652 0 Td
(high)Tj
2.0069 0 Td
(affinity)Tj
3.0671 0 Td
(tyrosine)Tj
3.4525 0 Td
(kinase)Tj
2.7496 0 Td
(receptor)Tj
3.5547 0 Td
(for)Tj
1.3889 0 Td
(hepatocyte)Tj
4.5241 0 Td
(growth)Tj
3.0727 0 Td
(factor)Tj
-34.1912 -1.3039 Td
(\(HGF\).[)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(])Tj
4.2859 0 Td
(Derailment)Tj
4.7792 0 Td
(of)Tj
1.0091 0 Td
(normal)Tj
3.1408 0 Td
(MET)Tj
2.2847 0 Td
(signaling)Tj
3.8154 0 Td
(is)Tj
0.8391 0 Td
(associated)Tj
4.2519 0 Td
(with)Tj
1.9899 0 Td
(invasive)Tj
3.4242 0 Td
(growth,)Tj
3.2939 0 Td
(tumor)Tj
2.7326 0 Td
(pro-)Tj
-35.8467 -1.2982 Td
(gression)Tj
3.5206 0 Td
(and)Tj
1.7347 0 Td
(metastases;)Tj
4.6602 0 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(])Tj
1.3719 0 Td
(aberrant)Tj
3.6114 0 Td
(MET)Tj
2.2903 0 Td
(signaling)Tj
3.8211 0 Td
(can)Tj
1.6271 0 Td
(result)Tj
2.4491 0 Td
(from)Tj
2.2053 0 Td
(MET)Tj
2.2961 0 Td
(over-expression,)Tj
-29.5878 -1.2983 Td
(amplification)Tj
5.5388 0 Td
(or)Tj
1.0942 0 Td
(mutations,)Tj
4.507 0 Td
(all)Tj
1.1452 0 Td
(of)Tj
1.0148 0 Td
(which)Tj
2.6532 0 Td
(are)Tj
1.4514 0 Td
(relevant)Tj
3.4185 0 Td
(in)Tj
1.0318 0 Td
(NSCLC.[)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
4.5638 0 Td
(5)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
0.9241 0 Td
(6)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
0.9184 0 Td
(7)Tj
0 g
(])Tj
1.0375 0 Td
(MET)Tj
2.2903 0 Td
(amplification)Tj
-31.589 -1.3039 Td
(predicts)Tj
3.4072 0 Td
(worse)Tj
2.5681 0 Td
(survival)Tj
3.3392 0 Td
(in)Tj
1.0318 0 Td
(NSCLC,)Tj
3.5263 0 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(])Tj
1.8482 0 Td
(it)Tj
0.788 0 Td
(has)Tj
1.5421 0 Td
(been)Tj
2.1203 0 Td
(implicated)Tj
4.4447 0 Td
(in)Tj
1.0374 0 Td
(520%)Tj
2.9197 0 Td
(of)Tj
1.0148 0 Td
(patients)Tj
3.3675 0 Td
(with)Tj
-32.9553 -1.2983 Td
(acquired)Tj
3.702 0 Td
(resistance)Tj
4.1329 0 Td
(to)Tj
1.0204 0 Td
(EGFR)Tj
2.6589 0 Td
(TKI)Tj
1.8425 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.7348 0 Td
(12)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.4003 0 Td
(13)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.3947 0 Td
(14)Tj
0 g
(])Tj
1.5136 0 Td
(and)Tj
1.7292 0 Td
(correlates)Tj
4.0762 0 Td
(with)Tj
2.0012 0 Td
(response)Tj
3.7304 0 Td
(to)Tj
1.0261 0 Td
(MET)Tj
2.2961 0 Td
(inhibi-)Tj
-34.2593 -1.2982 Td
(tor)Tj
1.3946 0 Td
(therapy)Tj
3.2485 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(].)Tj
2.0749 0 Td
(Blockade)Tj
3.8608 0 Td
(of)Tj
1.0148 0 Td
(MET)Tj
2.2904 0 Td
(is)Tj
0.8503 0 Td
(a)Tj
0.652 0 Td
(therapeutic)Tj
4.7338 0 Td
(strategy)Tj
3.3279 0 Td
(in)Tj
1.0318 0 Td
(EGFR)Tj
2.6589 0 Td
(TKI)Tj
1.8425 0 Td
(resistance.)Tj
4.354 0 Td
(The)Tj
1.7858 0 Td
(most)Tj
-35.121 -1.304 Td
(advanced)Tj
3.9911 0 Td
(agents,)Tj
2.9764 0 Td
(METMAb,)Tj
4.6034 0 Td
(a)Tj
0.652 0 Td
(MET)Tj
2.296 0 Td
(neutralizing)Tj
5.0286 0 Td
(antibody)Tj
3.7644 0 Td
(and)Tj
1.7292 0 Td
(Tivantinib,)Tj
4.6487 0 Td
(a)Tj
0.6577 0 Td
(small)Tj
2.3244 0 Td
(molecule)Tj
-32.6719 -1.2982 Td
(inhibitor)Tj
3.7813 0 Td
(of)Tj
1.0148 0 Td
(MET)Tj
2.2904 0 Td
(have)Tj
2.0636 0 Td
(both)Tj
2.058 0 Td
(failed)Tj
2.4037 0 Td
(in)Tj
1.0375 0 Td
(phase)Tj
2.4831 0 Td
(III)Tj
1.2416 0 Td
(clinical)Tj
3.0784 0 Td
(trials)Tj
2.194 0 Td
([)Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(];)Tj
2.0806 0 Td
(despite)Tj
3.0331 0 Td
(this,)Tj
1.9049 0 Td
(there)Tj
2.262 0 Td
(is)Tj
0.8504 0 Td
(consider-)Tj
-33.7774 -1.2983 Td
(able)Tj
1.8311 0 Td
(interest)Tj
3.2088 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(therapeutic)Tj
4.7339 0 Td
(potential)Tj
3.7587 0 Td
(of)Tj
1.0148 0 Td
(MET)Tj
2.296 0 Td
(inhibition)Tj
4.2236 0 Td
(in)Tj
1.0375 0 Td
(NSCLC.)Tj
3.5206 0 Td
(In)Tj
1.1055 0 Td
(fact,)Tj
1.8935 0 Td
(Crizotinib,)Tj
4.5524 0 Td
(a)Tj
-35.6822 -1.2983 Td
(MET)Tj
2.2903 0 Td
(proto-oncogene,)Tj
6.8428 0 Td
(receptor)Tj
3.5603 0 Td
(tyrosine)Tj
3.4469 0 Td
(kinase)Tj
2.7553 0 Td
(\(MET\))Tj
2.9707 0 Td
(tyrosine)Tj
3.4525 0 Td
(kinase)Tj
2.7496 0 Td
(inhibitor)Tj
3.7814 0 Td
(\(TKI\))Tj
2.5228 0 Td
(is)Tj
0.8504 0 Td
(cur-)Tj
-35.223 -1.3039 Td
(rently)Tj
2.5625 0 Td
(in)Tj
1.0374 0 Td
(clinical)Tj
3.0728 0 Td
(trial)Tj
1.8368 0 Td
(showing)Tj
3.583 0 Td
(good)Tj
2.228 0 Td
(results)Tj
2.8063 0 Td
(for)Tj
1.3889 0 Td
(both)Tj
2.058 0 Td
(MET)Tj
2.2904 0 Td
(amplification)Tj
5.5388 0 Td
(and)Tj
1.7291 0 Td
(MET)Tj
2.2961 0 Td
(exon)Tj
2.1656 0 Td
(14)Tj
-34.5937 -1.2982 Td
(skipping)Tj
3.6566 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(].)Tj
-2.4604 -1.2983 Td
(MET)Tj
2.296 0 Td
(may)Tj
1.9276 0 Td
(exert)Tj
2.1996 0 Td
(its)Tj
1.1509 0 Td
(oncogenic)Tj
4.3313 0 Td
(effects)Tj
2.7269 0 Td
(through)Tj
3.4469 0 Td
(crosstalk)Tj
3.7191 0 Td
(with)Tj
1.9955 0 Td
(other)Tj
2.3471 0 Td
(membrane)Tj
4.5694 0 Td
(receptors)Tj
-31.9065 -1.3039 Td
(including)Tj
4.0421 0 Td
(the)Tj
1.4684 0 Td
(EGFR)Tj
2.6532 0 Td
(family,)Tj
2.9537 0 Td
(as)Tj
1.0148 0 Td
(evidenced)Tj
4.2406 0 Td
(by)Tj
1.1848 0 Td
(MET)Tj
2.2904 0 Td
(and)Tj
1.7291 0 Td
(EGFR)Tj
2.6589 0 Td
(co-expression)Tj
5.743 0 Td
(in)Tj
1.0374 0 Td
(lung)Tj
2.007 0 Td
(cancer)Tj
2.8459 0 Td
(cell)Tj
-35.8693 -1.2983 Td
(lines,)Tj
2.2903 0 Td
([)Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(])Tj
1.8539 0 Td
(crosstalk)Tj
3.719 0 Td
(between)Tj
3.5263 0 Td
(EGFR)Tj
2.6532 0 Td
(and)Tj
1.7291 0 Td
(MET)Tj
2.2961 0 Td
(signaling)Tj
3.821 0 Td
(pathways)Tj
3.9345 0 Td
(and)Tj
1.7291 0 Td
(direct)Tj
2.5285 0 Td
(co-immunopre-)Tj
-30.081 -1.2983 Td
(cipitation.[)Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
5.7883 0 Td
(17)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.3946 0 Td
(18)Tj
0 g
(])Tj
1.5137 0 Td
(Moreover,)Tj
4.3993 0 Td
(MET)Tj
2.2904 0 Td
(amplification)Tj
5.5389 0 Td
(in)Tj
1.0374 0 Td
(association)Tj
4.6262 0 Td
(with)Tj
/F12 1 Tf
1.9955 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(mutations)Tj
-31.1355 -1.3039 Td
(additionally)Tj
4.9776 0 Td
(has)Tj
1.542 0 Td
(a)Tj
0.652 0 Td
(worse)Tj
2.5681 0 Td
(clinical)Tj
3.0784 0 Td
(prognosis)Tj
4.1216 0 Td
(than)Tj
/F12 1 Tf
2.0296 0 Td
[()]TJ
/F7 1 Tf
2.5511 0 Td
(mutations)Tj
4.2803 0 Td
(alone.[)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(])Tj
4.235 0 Td
(In)Tj
1.1111 0 Td
(light)Tj
2.024 0 Td
(of)Tj
1.0148 0 Td
(these)Tj
-34.1856 -1.2982 Td
(observations,)Tj
5.4821 0 Td
(we)Tj
1.3323 0 Td
(sought)Tj
2.9027 0 Td
(to)Tj
1.0261 0 Td
(understand)Tj
4.7905 0 Td
(the)Tj
1.4683 0 Td
(importance)Tj
4.8303 0 Td
(of)Tj
1.0148 0 Td
(EGFR)Tj
2.6532 0 Td
(and)Tj
1.7291 0 Td
(MET)Tj
2.296 0 Td
(interaction)Tj
4.6091 0 Td
(and)Tj
1.7292 0 Td
(we)Tj
-35.8637 -1.2983 Td
(have)Tj
2.0579 0 Td
(hypothesized)Tj
5.4708 0 Td
(that)Tj
1.7745 0 Td
(the)Tj
1.474 0 Td
(efficacy)Tj
3.2201 0 Td
(of)Tj
1.0148 0 Td
(MET)Tj
2.2961 0 Td
(inhibition)Tj
4.2236 0 Td
(can)Tj
1.6271 0 Td
(be)Tj
1.1508 0 Td
(influenced)Tj
4.4447 0 Td
(by)Tj
/F12 1 Tf
1.1792 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(mutation)Tj
-32.4848 -1.3039 Td
(status.)Tj
2.7269 0 Td
(We)Tj
1.6044 0 Td
(explored)Tj
3.702 0 Td
(this)Tj
1.6781 0 Td
(hypothesis)Tj
4.4617 0 Td
(by)Tj
1.1849 0 Td
(evaluating)Tj
4.3199 0 Td
(the)Tj
1.4684 0 Td
(response)Tj
3.7303 0 Td
(of)Tj
1.0148 0 Td
(three)Tj
2.2677 0 Td
(lung)Tj
2.007 0 Td
(adenocarcinoma)Tj
-30.1661 -1.2983 Td
(cell)Tj
1.559 0 Td
(lines)Tj
2.0636 0 Td
(that)Tj
1.7802 0 Td
(differ)Tj
2.3867 0 Td
(only)Tj
1.9729 0 Td
(in)Tj
1.0375 0 Td
(their)Tj
/F12 1 Tf
2.1089 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(genotype)Tj
3.8551 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4684 0 Td
(MET)Tj
2.296 0 Td
(inhibitor)Tj
3.7814 0 Td
(SGX523)Tj
/F12 1 Tf
3.4923 0 Td
[()12()]TJ
1.0148 0 Td
[()-13()14()7( )20(\n)]TJ
/F7 1 Tf
2.0409 0 Td
(and)Tj
1.7348 0 Td
(in)Tj
-36.1698 -1.2982 Td
(a)Tj
0.6519 0 Td
(murine)Tj
3.1805 0 Td
(xenograft)Tj
4.0195 0 Td
(model)Tj
2.7439 0 Td
(derived)Tj
3.2145 0 Td
(from)Tj
2.2053 0 Td
(the)Tj
1.474 0 Td
(same)Tj
2.2564 0 Td
(cells.)Tj
2.1429 0 Td
(Our)Tj
1.8652 0 Td
(data)Tj
1.9162 0 Td
(suggest)Tj
3.1238 0 Td
(that)Tj
1.7745 0 Td
(EGFR)Tj
2.6589 0 Td
(mutations)Tj
-33.2275 -1.2983 Td
(can)Tj
1.627 0 Td
(determine)Tj
4.32 0 Td
(the)Tj
1.4683 0 Td
(effect)Tj
2.3698 0 Td
(of)Tj
1.0148 0 Td
(MET)Tj
2.2904 0 Td
(inhibition)Tj
4.2236 0 Td
(independently)Tj
5.9754 0 Td
(of)Tj
1.0147 0 Td
(MET)Tj
2.2961 0 Td
(copy)Tj
2.1203 0 Td
(number,)Tj
3.6453 0 Td
(by)Tj
1.1792 0 Td
(changing)Tj
-33.5449 -1.3039 Td
(EGFR-MET)Tj
5.0739 0 Td
(dimerisation.)Tj
5.5389 0 Td
(As)Tj
1.2642 0 Td
(tumor)Tj
2.744 0 Td
(behaviour)Tj
4.2406 0 Td
(is)Tj
0.8504 0 Td
(modulated)Tj
4.5297 0 Td
(by)Tj
1.1849 0 Td
(this)Tj
1.6724 0 Td
(interaction,)Tj
4.8302 0 Td
(this)Tj
1.6781 0 Td
(could)Tj
-33.6073 -1.2983 Td
(determine)Tj
4.3199 0 Td
(treatment)Tj
4.1386 0 Td
(efficacy.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 195.9874 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Results)Tj
/F0 1 Tf
0 -1.4976 Td
(EGFR-MET)Tj
5.4189 0 Td
(interaction)Tj
4.7717 0 Td
(is)Tj
0.9307 0 Td
(modulated)Tj
4.8331 0 Td
(by)Tj
/F6 1 Tf
1.2614 0 Td
(EGFR)Tj
/F0 1 Tf
2.9859 0 Td
(mutations)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 161.0078 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(To)Tj
1.3379 0 Td
(assess)Tj
2.5228 0 Td
(if)Tj
0.771 0 Td
(EGFR-MET)Tj
5.0797 0 Td
(interaction)Tj
4.6091 0 Td
(is)Tj
0.8447 0 Td
(modified)Tj
3.8494 0 Td
(by)Tj
/F12 1 Tf
1.1792 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(mutations,)Tj
4.5071 0 Td
(we)Tj
1.3266 0 Td
(first)Tj
1.8085 0 Td
(generated)Tj
4.1328 0 Td
(two)Tj
-34.52 -1.2982 Td
(novel)Tj
2.398 0 Td
(cell)Tj
1.5591 0 Td
(lines)Tj
2.0693 0 Td
(by)Tj
1.1792 0 Td
(modification)Tj
5.3744 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(NCI-H1975)Tj
4.9832 0 Td
(lung)Tj
2.007 0 Td
(adenocarcinoma)Tj
6.8881 0 Td
(cell)Tj
1.559 0 Td
(line)Tj
1.7065 0 Td
(that)Tj
1.7801 0 Td
(harbours)Tj
-33.9871 -1.3039 Td
(L858R)Tj
2.8062 0 Td
(and)Tj
1.7292 0 Td
(T790M)Tj
3.1521 0 Td
(\(L858R/T790M\))Tj
6.7464 0 Td
(mutant)Tj
3.1464 0 Td
(EGFR)Tj
2.6532 0 Td
(\(to)Tj
1.3663 0 Td
(be)Tj
1.1509 0 Td
(referred)Tj
3.4185 0 Td
(to)Tj
1.0262 0 Td
(from)Tj
2.2053 0 Td
(here)Tj
1.9672 0 Td
(on)Tj
1.2756 0 Td
(as)Tj
-32.6435 -1.2983 Td
(H1975)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 226.7149 126.4251 cm
BT
/F7 1 Tf
1 TL
-0.0053 Tc
0 0 Td
(L858R/T790M)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 270.4251 122.0031 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(\).)Tj
0.788 0 Td
(We)Tj
1.61 0 Td
(used)Tj
2.058 0 Td
(lentiviral)Tj
3.7757 0 Td
(shRNA)Tj
3.1521 0 Td
(knockdown)Tj
4.9606 0 Td
(of)Tj
1.0148 0 Td
(EGFR)Tj
2.6532 0 Td
(\(targeting)Tj
4.1329 0 Td
(the)Tj
1.4683 0 Td
(5')Tj
0.9128 0 Td
(UTR)Tj
2.1883 0 Td
(of)Tj
-35.7559 -1.2982 Td
(EGFR\))Tj
2.9934 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(H1975)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 281.707 113.4425 cm
BT
/F7 1 Tf
1 TL
-0.0053 Tc
0 0 Td
(L858R/T790M)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 325.4173 109.0204 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(,)Tj
0.4478 0 Td
(followed)Tj
3.651 0 Td
(by)Tj
1.1792 0 Td
(transfection)Tj
4.989 0 Td
(with)Tj
1.9955 0 Td
(a)Tj
0.6577 0 Td
(plasmid)Tj
3.3902 0 Td
(encoding)Tj
3.9345 0 Td
(wild/type)Tj
-32.7852 -1.3039 Td
(\(wt\))Tj
/F12 1 Tf
1.8821 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(and)Tj
/F12 1 Tf
1.7291 0 Td
[()]TJ
/F7 1 Tf
2.5512 0 Td
(with)Tj
1.9956 0 Td
(the)Tj
1.4683 0 Td
(L858R)Tj
2.8062 0 Td
(mutation,)Tj
4.1499 0 Td
(to)Tj
1.0205 0 Td
(generate)Tj
3.6113 0 Td
(the)Tj
1.4683 0 Td
(H1975)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 479.0551 100.4598 cm
BT
/F7 1 Tf
1 TL
-0.0053 Tc
0 0 Td
(WT)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 493.0582 95.9811 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.4683 0 Td
(H1975)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 551.7354 100.4598 cm
BT
/F7 1 Tf
1 TL
-0.0053 Tc
0 0 Td
(L858R)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 82.9984 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(cell)Tj
1.559 0 Td
(lines)Tj
2.0636 0 Td
(respectively.)Tj
5.1137 0 Td
(Relative)Tj
3.3845 0 Td
(allele)Tj
2.245 0 Td
(frequency)Tj
4.184 0 Td
(\()Tj
/F12 1 Tf
[(\r)]TJ
3.0727 0 Td
[()2()]TJ
/F7 1 Tf
(.)Tj
/F12 1 Tf
1.2132 0 Td
[()]TJ
/F7 1 Tf
(\))Tj
3.4186 0 Td
(in)Tj
1.0318 0 Td
(these)Tj
2.2563 0 Td
(cell)Tj
1.5591 0 Td
(lines)Tj
2.0636 0 Td
(was)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 435.0614 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(MET-EG)Tj
3.848 0 Td
(FR)Tj
1.5449 0 Td
(Dimeriz)Tj
3.3237 0 Td
(ation)Tj
2.3456 0 Td
(in)Tj
0.978 0 Td
(Lung)Tj
2.4024 0 Td
(Cancer)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.4748 0 Td
(DOI:10.137)Tj
5.0387 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.0170)Tj
3.5434 0 Td
(798)Tj
2.6362 0 Td
(January)Tj
3.7134 0 Td
(31,)Tj
1.5874 0 Td
(2017)Tj
37.8003 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(19)Tj
/F10 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(Foundation)Tj
4.3512 0 Td
(Trust)Tj
2.1543 0 Td
(and)Tj
1.5874 0 Td
(the)Tj
1.3678 0 Td
(Crick)Tj
2.0905 0 Td
(Institute)Tj
3.2245 0 Td
(\(GS)Tj
1.637 0 Td
(and)Tj
-16.4127 -1.3748 Td
(WO\).)Tj
/F9 1 Tf
0 -2.126 Td
(Competing)Tj
4.3795 0 Td
(Interests)Tj
3.3307 0 Td
(:)Tj
/F10 1 Tf
0.4819 0 Td
(The)Tj
1.5875 0 Td
(authors)Tj
3.0401 0 Td
(have)Tj
1.963 0 Td
(declared)Tj
-14.7827 -1.3749 Td
(that)Tj
1.6228 0 Td
(no)Tj
1.1693 0 Td
(competing)Tj
4.1599 0 Td
(interests)Tj
ET
endstream
endobj
43 0 obj
<>stream
endstream
endobj
44 0 obj
<>stream
endstream
endobj
45 0 obj
<>stream
endstream
endobj
46 0 obj
<>stream
endstream
endobj
47 0 obj
<>stream
endstream
endobj
48 0 obj
<>stream
endstream
endobj
49 0 obj
<>stream
endstream
endobj
50 0 obj
<>stream
endstream
endobj
51 0 obj
<>stream
endstream
endobj
52 0 obj
<>stream
endstream
endobj
53 0 obj
<>stream
endstream
endobj
54 0 obj
<>stream
endstream
endobj
55 0 obj
<>stream
endstream
endobj
56 0 obj
<>stream
endstream
endobj
57 0 obj
<>stream
endstream
endobj
58 0 obj
<>stream
endstream
endobj
59 0 obj
<>stream
endstream
endobj
60 0 obj
<>stream
endstream
endobj
61 0 obj
<>stream
endstream
endobj
62 0 obj
<>stream
endstream
endobj
63 0 obj
<>stream
BT
10.3394 79.2147 Td
(exist.)Tj
ET
Q
endstream
endobj
64 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 69 0 R/Contents 70 0 R/TrimBox[0 0 612 792]>>
endobj
68 0 obj
<>stream
JFIF C
$, !$4.763.22:ASF:=N>22HbINVX]^]8EfmeZlS[]Y C**Y;2;YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY o"
} !1AQa"q2#BR$3br
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz
w !1AQaq"2B #3Rbr
$4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ? (
($ Ihh˩onRvؕe md"
^^\Im!<=zPE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE R $KY z =c |??W}6 6"~ BMD$+O^; G-RimmHo9>5O-Ms
czZ4n::z Ң( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( w:|7pIFsԌt>fq,qA:j N[T$>sN@UM6+ef>۾g|.N%B>]-Zj!)8P]MS_,۲\xpkfniT$L{kԨ ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( {EKe
hV~ " ^ >~_EYǕs__: C0{@QðiŨF zg=UqeCx6